Funding News

Aragen Life Sciences Has Filed Its DRHP With SEBI — India's Largest CRDMO by Solutions Offered Is Going Public With a Rs 3,500 Crore IPO

By Mustafa Shariff, Editor in Chief · September 02,2026 · 2 mins read

Summary

• Aragen Life Sciences Files DRHP With SEBI: India's Largest CRDMO Eyes Rs 3,500 Crore IPO — Goldman Sachs and Quadria Backed Platform Goes Public
• Aragen Life Sciences (formerly GVK Biosciences) filed its DRHP with SEBI on August 27, 2026 for an IPO comprising Rs 800 crore fresh issue + OFS up to 27.33 million shares, targeting up to Rs 3,500 crore — the largest Indian CRDMO IPO of 2026.

"This IPO represents the next chapter of Aragen's journey — from a discovery-focused CRO to a fully integrated CRDMO serving global innovators across the entire drug development lifecycle. With more than 25 years of operations, more than 4,000 scientists, and capabilities spanning small molecules, biologics, and ADCs across discovery, development, and commercial manufacturing, we have built a platform that can support our partners from first molecule to final market. The capital raised will accelerate our infrastructure investments in Hyderabad and Bengaluru and help us serve the growing outsourcing needs of global pharmaceutical innovators."

Aragen Life Sciences, the Hyderabad-headquartered contract research, development and manufacturing organisation (CRDMO), filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on August 27, 2026. The filing is for an initial public offering comprising a fresh issue of Rs 800 crore and an offer for sale of up to 27,329,192 equity shares (face value Rs 10 each) by selling shareholders — with the total IPO expected to raise up to Rs 3,500 crore.
Who Aragen Is
Aragen Life Sciences was incorporated in 2000 and operated for many years as GVK Biosciences — a name well-known across the global pharmaceutical CRO industry for its chemistry and biology outsourcing capabilities. The company rebranded to Aragen in 2021 when Goldman Sachs became a strategic investor, marking the company's transition from a discovery-focused CRO to a fully integrated CRDMO spanning the complete drug development lifecycle from discovery research to commercial manufacturing.
At the time of DRHP filing, Aragen describes itself as India's largest CRDMO among assessed Indian peers by number of solutions offered across the drug development value chain, and among the top three Indian CRDMOs by operating revenue. The global CRDMO market was estimated at $171 billion in fiscal 2026 — and Aragen's positioning across both CRO (discovery and preclinical research) and CDMO (development and commercial manufacturing) for small molecules and biologics places it uniquely across the full lifecycle value chain.
The IPO Structure and Use of Proceeds
The Rs 800 crore fresh issue proceeds will be deployed for: repayment and pre-payment of borrowings, capital expenditure for purchase of new equipment and machinery at Aragen's Hyderabad facilities, capital expenditure for its subsidiary Aragen Biologics at its Bengaluru facility, and general corporate purposes. The Bengaluru allocation reflects Aragen Biologics' growing importance as the biologics CDMO arm — a capability that is increasingly critical as the global shift toward biologics outsourcing accelerates under BIOSECURE Act pressure.
The Investor Backing: Goldman Sachs and Quadria Capital
Goldman Sachs became a strategic investor in Aragen when the company rebranded from GVK Biosciences — providing not just capital but the global life sciences network relationships that have helped Aragen expand its innovator pharma and biotech client base across the US and Europe. In January 2026, Quadria Capital invested $100 million in Aragen, acquiring a minority stake at a valuation of approximately $1.4 billion. With investment, Quadria joined Goldman Sachs as the second strategic investor. The combined investor backing signals strong institutional conviction in Aragen's CRDMO platform as a leading India beneficiary of the BIOSECURE Act-driven outsourcing shift.
The BIOSECURE Act Context
BHC Media has covered the BIOSECURE Act's escalating implementation throughout 2026 — WuXi AppTec's Pentagon 1260H listing, the BIOSECURE designation expected December 2026, and the five-year grace period that creates the main commercial wave between 2028 and 2033. Laurus Labs' 67% CDMO revenue growth in Q1 FY27 (covered July 27 edition) and Piramal Pharma Solutions' $90M infrastructure expansion are examples of India CDMO companies already monetising this tailwind. Aragen's IPO — if listed and well-received — creates a publicly traded vehicle for investors to participate in this same structural demand shift.
BHC Perspective
At Bengaluru Health Community, Aragen's SEBI DRHP filing is the most significant event in India's CDMO sector equity story since Laurus Labs and Divi's Laboratories demonstrated what a well-run CDMO looks like on public markets. For BHC founders in CDMO services, pharmaceutical outsourcing, or CRDMO technology platforms — the Aragen IPO defines the valuation framework for India's CRDMO sector at the current moment. For BHC mentors who are life sciences investors — the Aragen DRHP filing is required reading.
Frequently Asked Questions
Q: What is Aragen Life Sciences' IPO?
A: DRHP filed with SEBI on August 27, 2026. IPO: Rs 800 crore fresh issue + OFS of up to 27,329,192 equity shares, total expected raise up to Rs 3,500 crore. Formerly GVK Biosciences, Hyderabad-based. India's largest CRDMO by solutions offered. CEO: Manni Kantipudi.
Q: Who are the key investors?
A: Goldman Sachs (strategic investor since 2021 rebrand). Quadria Capital ($100 million investment, January 2026, at ~$1.4 billion valuation — joining as second strategic investor). Both are selling shareholders in the OFS component.
Q: How will fresh issue proceeds be used?
A: Debt repayment, capex at Hyderabad facilities, capex for Aragen Biologics at Bengaluru (for biologics manufacturing expansion), and general corporate purposes.